• Listen Live NOW!
  • On Demand
  • Ways to Listen
  • All Shows
    • Radio Shows
      • 1st Talk Compliance
      • Conversations on Health Care
      • FINN Voices
      • Harlow on Healthcare
      • Healthcare De Jure
      • Healthcare IT Today
      • Health UnaBASHEd
      • News You Can Use
      • PopHealth Week
      • The Incrementalist
      • The Scope with Dr. K
      • The Tate Chronicles
      • The Virtual Shift
      • This Just In Radio Show
      • Trending NOW
      • Value-Based Care Insights
    • Podcast Shows
      • 4sight Health Roundup
      • Ambulatory Healthcare Today
      • AMCP Podcast Series – Listen Up
      • Ask the Educator
      • Beyond the Needle
      • Healthcare for Humans
      • Healthcare Rap
      • HealthLaw HotSpot
      • Hello Healthcare Podcast
      • In Network’s Podcast Feature: Designing for Health
      • Meeting of the Minds
      • The Brain Trust
      • The Digital Patient
      • The Handoff
    • Monthly Podcast Shows
      • Follow the Medical Record
      • Healthcare TechTalk with Brillio
      • Life-Centered Health Care
      • Tell Me Where IT Hurts
      • The Dish on Health IT
      • The Healthusiasm Podcast
      • Voices of Change
      • Voices of Self Funding
      • What’s My Tagline
  • Playlists
  • NursesNOW
    • Nursing News
      • Organizations
      • Podcasts
  • Conferences
  • Request Media Kit
  • Contact Us
Event Calendar
HealthcareNOWradio.comHealthcareNOWradio.com
  • Listen Live NOW!
  • On Demand
  • Ways to Listen
  • All Shows
    • Radio Shows
      • 1st Talk Compliance
      • Conversations on Health Care
      • FINN Voices
      • Harlow on Healthcare
      • Healthcare De Jure
      • Healthcare IT Today
      • Health UnaBASHEd
      • News You Can Use
      • PopHealth Week
      • The Incrementalist
      • The Scope with Dr. K
      • The Tate Chronicles
      • The Virtual Shift
      • This Just In Radio Show
      • Trending NOW
      • Value-Based Care Insights
    • Podcast Shows
      • 4sight Health Roundup
      • Ambulatory Healthcare Today
      • AMCP Podcast Series – Listen Up
      • Ask the Educator
      • Beyond the Needle
      • Healthcare for Humans
      • Healthcare Rap
      • HealthLaw HotSpot
      • Hello Healthcare Podcast
      • In Network’s Podcast Feature: Designing for Health
      • Meeting of the Minds
      • The Brain Trust
      • The Digital Patient
      • The Handoff
    • Monthly Podcast Shows
      • Follow the Medical Record
      • Healthcare TechTalk with Brillio
      • Life-Centered Health Care
      • Tell Me Where IT Hurts
      • The Dish on Health IT
      • The Healthusiasm Podcast
      • Voices of Change
      • Voices of Self Funding
      • What’s My Tagline
  • Playlists
  • NursesNOW
    • Nursing News
      • Organizations
      • Podcasts
  • Conferences
  • Request Media Kit
  • Contact Us

CMS Statement on FDA Accelerated Approval of Lecanemab

Jan 10, 2023 | Posted by Industry News | Healthcare |

The Centers for Medicare & Medicaid Services (CMS) (@CMSGov) is releasing the following statement from Administrator Chiquita Brooks-LaSure, with accompanying background information, in response to the action by the Food and Drug Administration (FDA) to grant accelerated approval to a new product designed to treat Alzheimer’s disease:

“Alzheimer’s disease is a devastating illness that affects millions of Americans and their families,” said CMS Administrator Chiquita Brooks-LaSure. “At CMS, we will continue to expeditiously review the data on these products as they become available and are committed to timely access to treatments, including drugs, that improve clinically meaningful outcomes.”

Additional Background Information:

CMS has a responsibility to ensure people with Medicare have appropriate access to therapies that are reasonable and necessary for use in the Medicare population. As announced in April 2022, CMS laid out how FDA-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease could be covered by Medicare. Because Eisai’s product, lecanemab, was granted accelerated approval by the FDA, it falls under CMS’s existing national coverage determination. CMS is examining available information and may reconsider its current coverage based on this review.

If lecanemab subsequently receives traditional FDA approval, CMS would provide broader coverage using the framework we announced last year, under coverage with evidence development, on the same day. For FDA traditional approval the drug demonstrates evidence of efficacy from a direct measure of clinical benefit. The same would apply to any monoclonal antibody directed against amyloid for the treatment of Alzheimer’s disease. View the national coverage determination.

In the April 2022 National Coverage Determination (NCD), CMS stated it was interested in data that could answer the following questions:

  • Does the antiamyloid mAb meaningfully improve health outcomes (i.e., slow the decline of cognition and function) for patients in broad community practice?
  • Do benefits, and harms such as brain hemorrhage and edema, associated with use of the antiamyloid mAb, depend on characteristics of patients, treating clinicians, and settings?
  • How do the benefits and harms change over time?

CMS continues to actively engage with all interested stakeholders and is reviewing data that may answer these Coverage with Evidence Development (CED) questions that were listed in the April 2022 NCD. CMS encourages any stakeholder to send relevant data to assist in a reconsideration of the current coverage.

CMS follows a standard and formal process to develop or reconsider NCDs that includes opportunities for the public to participate and submit comments. Per the statute, CMS generally issues a proposed NCD and accompanying decision memorandum within six months from the initiation of the NCD analysis. When the proposed NCD is issued, it will initiate a 30-day public comment period with the final NCD due within 60 days from end of the 30-day public comment period. View additional information on the NCD process (August 2013 FR notice) and (CMS Coverage webpage regarding the Medicare Coverage Determination Process).

Share on twitter
Twitter
Share on linkedin
Linkedin
Share on facebook
Facebook
Share on pinterest
Pinterest
Share on reddit
Reddit
Share on email
Email
Share this...
Tags: Alzheimer'sChiquita Brooks-LaSureCMSFDA

Radio for the Healthcare Industry

No HTML5 audio playback capabilities for this browser. Use Chrome Browser!

Categories

Get our News Digest

Get Our News Digest


Thank you!

You have successfully joined our subscriber list.

.

About HealthcareNOWRadio.com

HealthcareNOWradio.com is an Internet radio station operated and produced as part of Answers Media Network. The station offers interviews, and commentary from industry leaders in healthcare and health information technology, as well as originally produced programming hosted by industry leaders. Listen on any device 24/7. You can also subscribe to get notification when a new show airs.

Sign Up for Our e-News Digest

Get notified when a new show airs or when your favorites are available as podcasts. Sign up here

Our News Media Site

Connect with Us

Contact Us

Contact a Host

Media Kit

Listening Guide

 

Follow Us

Upcoming Conferences

Oct 3
October 3 - October 5

HITRUST Collaborate 2023

Grapevine
Oct 4
October 4 - October 6

BioFuture

New York
Oct 8
October 8 - October 10

AHIMA23 Conference

Baltimore
View Calendar

©2023 Answers Media Company, LLC

  • Healthcare NOW Radio Media Kit
  • Contact Us
  • Our Privacy Policy
  • Our Guests and Recording Policy
Prev Next